Vizamyl
- Generic Name: flutemetamol f 18 injection
- Brand Name: Vizamyl
- Drug Class: How Do Diagnosing Imaging Agents Work?
Vizamyl (Flutemetamol F 18 Injection) side effects drug center
- Related Drugs
- Health Resources
- flushing (warmth, redness, or tingling feeling of the skin)
- increased blood pressure
- headache
- nausea, and
- dizziness
What Is Vizamyl?
Vizamyl (flutemetamol F 18) Injection is a molecular imaging agent used for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.
What Are Side Effects of Vizamyl?
Common side effects of Vizamyl include:
Dosage for Vizamyl
The recommended dose for Vizamyl is 185 megabecquerels (MBq) [5 millicuries (mCi)] in a maximum dose volume of10 mL, administered as a single intravenous bolus with in 40 seconds. The maximum mass dose is 20 micro grams.
What Drugs, Substances, or Supplements Interact with Vizamyl?
Vizamyl may interact with other drugs. Tell your doctor all medications and supplements you use.
Vizamyl During Pregnancy and Breastfeeding
During pregnancy, Vizamyl should be used only if prescribed. Vizamyl should not be used during breastfeeding for 24 hours after exposure to Vizamyl. Consult your doctor before breastfeeding.
Additional Information
Our Vizamyl (flutemetamol F 18) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Vizamyl Professional Information
SIDE EFFECTS
Clinical Trials Experience
Clinical trials are conducted under widely varying conditions and adverse reaction rates observed in the clinical trials of Vizamyl cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
In clinical trials, 761 adults (367 men and 394 women, 91% Caucasian) with a mean age of 62 years (range 18-93 years) received Vizamyl. Most subjects (530, 70%) received a dose of 185 MBq (5 mCi).
One subject out of 761 administered Vizamyl experienced a serious hypersensitivity reaction with flushing, dyspnea and chest pressure within minutes following Vizamyl administration and recovered with treatment.
Most adverse reactions were mild to moderate in intensity and resolved spontaneously. The most commonly reported adverse reactions (occurring in at least 1% of subjects) in Vizamyl-treated subjects are shown in Table 2.
Table 2: Adverse Reactions Reported in Clinical Trials of Vizamyl (N = 761 subjects)
| Adverse Reaction | N (percent of patients) |
| Flushing | 16 (2%) |
| Increased blood pressure | 13 (2%) |
| Headache | 10 (1%) |
| Nausea | 8 (1%) |
| Dizziness | 8 (1%) |
Read the entire FDA prescribing information for Vizamyl (Flutemetamol F 18 Injection)